# MolecuLight *i:X* Wound Imaging Device

Incorporating the MolecuLight *i:X* into standard care helps clinicians measure wounds<sup>1,2</sup> and detect fluorescent bacteria<sup>3-7</sup> to facilitate evidence-based clinical decision-making in these areas of wound management:



In a multisite, clinical trial, red fluorescence on MolecuLight *i:X* images was indicative of bacterial loads of ≥10<sup>4</sup> CFU/g (moderate/heavy levels) 100% of the time.<sup>4</sup> This real-time information, used in conjunction with clinical signs and symptoms, may assist a clinician in their wound assessment and treatment plan.



## **DEBRIDEMENT**

In clinical studies and case series, the MolecuLight *i:X* has been shown to demonstrate the need for debridement, identify the extent of debridement required, and facilitate targeted debridement to areas where fluorescent bacteria are located.<sup>3,6,9</sup>



## **DOCUMENTATION**

Provides objective documentation of the presence of fluorescent bacteria<sup>3-7</sup> and the surface area of the wound.<sup>1,2</sup>



## **ANTIMICROBIAL STEWARDSHIP**

In case series, real-time fluorescence images prevented potentially unnecessary use of systemic and topical antibiotics in wound patients<sup>6</sup> and identified asymptomatic wound patients with heavy bacterial burden, prompting antibiotic prescription.<sup>6,14</sup>



## CLEANING

In case series, the MolecuLight *i:X* has been shown to direct clinician focus for cleaning to areas where fluorescent bacteria are located, <sup>6,8</sup> thereby optimizing wound bed preparation.<sup>8</sup>



## **SAMPLING**

Guides where to sample; 4-6,10 in a clinical trial, fluorescence targeted sampling was more accurate than standard practice in detecting the presence of moderate to heavy bacterial loads. A meta-analysis reported an average fluorescence-guided sampling accuracy of 86%. 11




### TREATMENT SELECTION

In a case series, fluorescence images provided real-time, objective documentation to support skin graft procedures;<sup>11</sup> planned grafting procedures were halted when fluorescent bacteria were visualized.<sup>11</sup> Clinical studies have shown that fluorescent images also provide real-time objective feedback on treatment plan effectiveness.<sup>6,11-13</sup>



## PATIENT ENGAGEMENT

In a clinical case study, fluorescence images facilitated patient engagement and were associated with an improvement in patient treatment plan adherence. <sup>15</sup> Patients easily understood the bright colors on images in regions where fluorescent bacteria were present. <sup>15</sup>



## MolecuLight *i:X*™ **Wound Imaging Device**



Bacteria appear red or cvan in image.



Portable, touch-screen device with an intuitive interface.7,10



No contrast agents and no patient contact required. 4,7,10



Allows for more targeted treatment protocols by knowing exactly where fluorescent bacteria are.3-7



## Efficient

Clinical studies have shown that fluorescent images assist in targeting sampling and debridement, and inform the decision whether or not to use an antimicrobial product.3-6



A clinical study reported that the acquisition of real-time fluorescence images takes less than 30 seconds.7



Allows clinicians to focus on areas that may contain harmful bacteria with the guidance of fluorescence imaging.4-6

### References:

- Dunham D et al. Objective wound measurement software on a point-of-care, hand-held fluorescence imaging device: verification of measurement accuracy and repeatability. Presented at EWMA 2018.
- Rennie MY et al. Accuracy and intra-user variability of a wound area measurement software. Presented at CAET 2017.
- DaCosta RS et al. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLOS ONE, 2015.
- Rennie MY et al. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. J Wound Care., 2017.

  Ottolino-Perry K et al. Improved detection of clinically relevant wound bacteria using autofluorescence image-guided sampling in diabetic foot ulcers. Int Wound J., 2017. Hill R et al. Using bacterial fluorescence imaging and antimicrobial stewardship to guide wound management practices: a case study. Ostomy Wound Manage., 2018
- Blumenthal E et al. The use of the MolecuLight i:X in managing burns: a pilot study. J Burn Care Res., 2017.
- Hill R et al. Shifting focus: implications of periwound bacterial load on wound hygiene. Presented at EWMA 2018.

  Raizman R. Targeting curettage debridement to regions of bioburden in diabetic foot ulcers (DFUs) with real-time bacterial fluorescence imaging. Presented at EWMA 2017.
- Blackshaw EL et al. Efficacy of an imaging device at identifying the presence of bacteria in wounds at a plastic surgery outpatients clinic. J Wound Care, 2018.
- Jeffery, S. The utility of MolecuLight bacterial sensing in the management of burns and traumatic wounds. The proceedings of SPIE 2019. In press. Raizman R. Handheld real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes in inpatients undergoing negative pressure wound therapy. Presented at
- Blumenthal E et al. Autofluorescence imaging for evaluating debridement in military and trauma wounds. Mil Med., 2018.
- Wu YC et al. Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. Int Wound J., 2016. Raizman R. Handheld real-time bacterial fluorescence imaging guides wound cleaning and facilitates patient education in pilonidal sinus wound care patients. Presented at EWMA 2017.

©2019 MolecuLight® Inc. All Rights Reserved. PN 1511 Rev 1.0

The MolecuLight £X<sup>TM</sup> Imaging Device is approved by Health Canada (Medical License #95784) and has CE marking (Certificate #G1160292355002) for sale in Canada and the European Union. The MolecuLight £X<sup>TM</sup> Imaging Device has received FDA De Novo clearance, please see https://us.moleculight.com/ for USA specific intended & indications for use.

MolecuLight® and Look to Heal® are Registered Trademarks in Canada, the EU, and the USA

